首页> 美国卫生研究院文献>Springer Open Choice >Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
【2h】

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer

机译:膀胱癌中对膀胱内BCG的临床反应中肿瘤内Th2易感性与Th1功能性表型增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded cancer tissue by immunohistochemistry to examine expression of transcription factors that control Th1 (T-bet) and Th2-type (GATA3) immunity. We confirmed a Th2 predisposition with a mean GATA3/T-bet ratio of 5.51. BCG responders showed significantly higher levels of urinary (p = 0.003) and serum neopterin (p = 0.012), kynurenine (p = 0.015), KTR (p = 0.005), IFN-γ (p = 0.005) and IL-12 (p = 0.003) during therapy, whereas levels of IL-10 decreased significantly (p < 0.001) compared to non-responders. GATA3/T-bet ratio correlated positively with serum neopterin (p = 0.008), IFN-γ (p = 0.013) and KTR (p = 0.018) after the first BCG instillation. We observed a significant increase in CD4 expression in the Th cell population (p < 0.05), with only a modest tendency toward higher frequency in responders compared to non-responders (p = 0.303). The combined assessment of GATA3/T-bet ratio, neopterin and KTR may be a useful biomarker in predicting BCG response. Th2-promoting factors such as GATA3 may trigger Th1-type immune responses and thus contribute to the BCG success.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-016-1945-z) contains supplementary material, which is available to authorized users.
机译:尽管最近已经报道了Th2介导的BCG应答者,但认为Th1型免疫是膀胱癌对BCG的有效应答所必需的。目的是评估23名接受BCG治疗的患者中Th1和Th2成分的关系。在基线,BCG期间和之后,前瞻性收集外周血,血清和尿液样本。 Th1(新蝶呤,色氨酸,犬尿氨酸,犬尿氨酸与色氨酸之比(KTR),IL-12,IFN-γ,可溶性TNF-R75和IL-2Rα)和Th2(IL-4,IL-10)生物标志物以及确定T辅助细胞(Th),效应子和调节性T细胞中的CD4表达。通过免疫组织化学法在福尔马林固定,石蜡包埋的癌组织上测量局部免疫细胞亚群,以检查控制Th1(T-bet)和Th2型(GATA3)免疫力的转录因子的表达。我们证实了Th2易感性,其GATA3 / T-bet平均比率为5.51。 BCG应答者显示尿(p = 0.003)和血清新蝶呤(p = 0.012),犬尿氨酸(p = 0.015),KTR(p = 0.005),IFN-γ(p = 0.005)和IL-12(p在治疗期间= 0.003),而与无反应者相比,IL-10水平显着降低(p <0.001)。第一次BCG滴注后,GATA3 / T-bet比值与血清新蝶呤(p = 0.008),IFN-γ(p = 0.013)和KTR(p = 0.018)呈正相关。我们观察到Th细胞群中CD4表达显着增加(p <0.05),与非反应者相比,反应者中只有较高的频率出现适度的趋势(p = 0.303)。 GATA3 / T-bet比,新蝶呤和KTR的综合评估可能是预测BCG反应的有用生物标志物。 Th2促进因子如GATA3可能触发Th1型免疫反应,从而有助于BCG成功。电子补充材料本文的在线版本(doi:10.1007 / s00262-016-1945-z)包含补充材料,可以通过以下途径获得给授权用户。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号